[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
Molecular Diagnostics Technologies Report
I enclose details of our Molecular Diagnostics Technologies Report.
Molecular diagnostic technologies offer the potential for moving from diagnostics to prognostics.
But what is ?molecular diagnostics? By definition, it includes all tests and methods to identify a disease or the predisposition for a disease analyzing Dna- or RNA of an organism.
Still, the market for molecular diagnostics is difficult to estimate as it overlaps with the in vitro diagnostic market and is less well defined than the pharmaceutical or device markets.
But in the post era of accomplishing the ?Human Genome Project?, molecular diagnostics is ready to get its due as the legitimate future business trend in healthcare.
The genomic discovery will fuel the diagnostic marketplace because every gene-based therapeutic might need an accompanying (molecular) diagnostic test.
At approximately 30.000 genes for the human genome and with an estimated diagnostic significance of about 5%, the commercialization of 1.500 gene-based tests can be expected.
The way is paved by infectious disease testing and blood banking applications, but pharmacogenetic, predisposition diagnostics and molecular cancer diagnostics applications will follow soon and post strong numbers in the years to come.
Cancer for instance, represents a set of diseases with vast unmet clinical need for improved diagnostics and therapeutics.
Cancer in the developed western countries with a prevalence between 1.0 and 1.5% depicts a large market with a high potential for R& D and fields like therapy specific diagnostics (theranostics).
Those segments with significant revenue potential will benefit from the advantages the molecular technologies present: sensitivity, specificity and speed.
In addition, non-invasive or minimal-invasive procedures to obtain the material for those tests will facilitate the implementation.
Cross-benefits like almost instant diagnostic results, more targeted therapies and shorter hospitalization times constitute higher costs for molecular test in comparison to traditional analyses like microbiology today.
But molecular diagnostics will help to abate cost for diagnosis, therapy and healthcare altogether in the middle-term.
If the expiration of the basic Pcr-licence in 2005 will affect prizes for molecular diagnostic tests remains to be seen, but prizes will drop clearly with the gradually automation of the tests.
For a complete index of this report click on http://www.researchandmarkets.com/reports/c1521
1.Executive Summary 5
2. Introduction 10
3. The Current Situation ? Public
Environment & Politics in Europe 17
3.1 Public Awareness 17
3.1.1 Who is the public 18
3.1.2 How to reach the end user 21
3.2 Patent situation? 22
3.3 Standardisation & Quality Measures 25
3.3.1 Harmonization of Standards 25
3.3.2 Molecular Diagnostics ? quick and
3.3.3 Standardized tests ? two sites of a
3.3.4 Who defines the standard? 32
3.4 Reimbursement & Prices 33
4. The Market of Molecular Diagnostics 39
4.1 Overview 39
4.2 Nucleic acid purification 50
4.2.1 The Market 50
4.2.2 Driver & Restraints 53
4.2.3 Forecasting 55
4.3 Nucleic acid Amplification 56
4.3.1 The Market 56
Amplification in infectious disease 57
Amplification in blood screening 58
Amplification in genetic testing 58
4.3.2 Amplification methods 59
Polymerase Chain Reaction 59
non-PCR amplification techniques 62
Automation of Amplification Methods 64
4.3.4 Driver and Restraints 66
4.3.5 Forecasting 68
5. NAT Applications 71
5.1. Blood testing and infectious diseases 71
5.1.1 The Market 71
5.1.2 Market Influences and Forecast 75
5.2. Cancer? 77
5.2.1 The Market 77
5.2.2 Market Influences and Forecast 79
5.3 SNPs - advantage of being a little different 80
5.3.1 The Market 80
5.3.2 Market Influences and Forecast 84
5.4 Food diagnostics 87
5.4.1 The Market 87
5.4.2 Strategies and Forecasting 89
6. Trends in Molecular Diagnostics 93
6.1 Pharmacogenomics 93
6.1.1 The Market 93
6.1.2 Market Influences and Forecast 96
6.2 DNA Microarrays 101
6.2.1 The Technique 101
6.2.2 The Market 102
Identification of sequence 102
Determination gen expression level 104
6.2.3 Emerging Markets of DNA Arrays 103
Human leukocyte antigen typing 108
Neonatal screening 108
6.2.4 Drivers and restraints 108
6.2.5 Forecast 112
7. Asia ? Market of Chance 115
7.1 The Market overview 115
7.2 Selected Asian markets? 117
7.2.1 The Elite 117
Australia and New Zealand 118
7.2.2 Developing Markets 118
7.3 Outlook 122
8. Companies 124
8.1. Merger & Acquisitions 124
8.1.1 The Situation 124
8.1.2 Merger 125
8.1.3 Alternatives 126
Strategic allies 126
8.2 Company profiles 128
Hard Copy EUR 3,500
Electronic EUR 3,500
ORDERING - FOUR EASY WAYS TO PLACE YOUR ORDER:
Order online: To order this report please click on http://www.researchandmarkets.com/reports/c1521
Order via email: mailto:email@example.com
Order via fax-back form: Click on http://www.researchandmarkets.com/reports/c1521 Fax to +353 1 4100 980
Order via post: Click on http://www.researchandmarkets.com/reports/c1521
Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland
Related Reports Available from Research & Markets Ltd:
The Diagnostics Outlook to 2005 - http://www.researchandmarkets.com/reports/1233
Molecular Diagnostics: Immediate Opportunities and Future Implications - http://www.researchandmarkets.com/reports/1304
The Emergency Room Database: The top drugs prescribed, diagnostics provided, providers seen, visit characteristics, payment source and more for over 2,600 diseases - http://www.researchandmarkets.com/reports/16359
The Hospital Outpatient Profile: The top drugs prescribed, diagnostics provided, providers seen, visit characteristics, payment source, disposition and more for over 2,400 diseases - http://www.researchandmarkets.com/reports/16360
Key Diagnostic Testing Markets - http://www.researchandmarkets.com/reports/7671
Medical and Diagnostic Laboratories in the US - http://www.researchandmarkets.com/reports/16906
Women?s Health: Diagnostic Tests - http://www.researchandmarkets.com/reports/28413
Biotechnologys Top 50 in Pharmaceuticals and Diagnostics: A Competitive Analysis (2001 Edition) - http://www.researchandmarkets.com/reports/1319
The Genomics Outlook To 2005: Transforming pharmaceutical and diagnostic markets - http://www.researchandmarkets.com/reports/1272
Cancer Diagnostics: Early Detection of Breast, Prostate and Colorectal Cancer - http://www.researchandmarkets.com/reports/1008
Drugs-Diagnostic Substances Value Set - http://www.researchandmarkets.com/reports/2988
Point of Care Diagnostic Testing - World Markets - http://www.researchandmarkets.com/reports/5489
Important Diagnostic Testing Markets - http://www.researchandmarkets.com/reports/5532
The Over the Counter Diagnostic Product Markets - http://www.researchandmarkets.com/reports/5534
Cancer Diagnostic Testing World Markets - http://www.researchandmarkets.com/reports/5538
Click on http://www.researchandmarkets.com for details.
Thank you for your consideration.
Research and Markets Ltd
REPORT DATA SUMMARY:
Molecular Diagnostics - Revolution or Hype
Subscribe: Click on http://www.researchandmarkets.com/register.asp You can subscribe free for regular details on new research in your sector.
Please note you are currently subscribed as firstname.lastname@example.org
If you no longer wish to receive our market research updates, please reply to this message with Suppression Request as the subject line, or use the link below